Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

PURPOSE: Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC). MATERI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Owonikoko, Taofeek K., Dahlberg, Suzanne E., Sica, Gabriel L., Wagner, Lynne I., Wade, James L., Srkalovic, Gordan, Lash, Bradley W., Leach, Joseph W., Leal, Ticiana B., Aggarwal, Charu, Ramalingam, Suresh S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6338394/
https://ncbi.nlm.nih.gov/pubmed/30523756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.00264
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados